Want to see AU:IDX full AI Analyst Report?
Top Page
Integral Diagnostics Ltd.
(Sydney:IDX)
Select Model
Select Model
Rating:60Neutral
Price Target:
AU$2.50
▲(7.30% Upside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by improving operational/cash-flow performance and solid top-line growth, tempered by volatile and currently modest net profitability plus moderate leverage. Technicals are supportive but appear overbought, and the high P/E valuation meaningfully drags the overall score.
Positive Factors
Strong Revenue Expansion
Revenue more than doubled across the period, indicating sustained scale expansion and demand for diagnostic imaging. A larger operating footprint can strengthen referral density, improve equipment utilisation and support more efficient delivery over the next several months.
Negative Factors
Volatile and Compressed Net Margins
The large loss in 2024 and incomplete margin recovery show that revenue growth has not translated consistently into shareholder earnings. Persistently modest net margins leave less buffer for labour, reimbursement or operating-cost pressures.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Expansion
Revenue more than doubled across the period, indicating sustained scale expansion and demand for diagnostic imaging. A larger operating footprint can strengthen referral density, improve equipment utilisation and support more efficient delivery over the next several months.
Read all positive factors
Integral Diagnostics Ltd. (IDX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$865.02M
Dividend Yield4.39%
Average Volume (3M)1.27M
Price to Earnings (P/E)38.8
Beta (1Y)0.64
Revenue Growth25.73%
EPS Growth390.83%
CountryAU
Employees3,049
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.06
Shares Outstanding373,066,530
10 Day Avg. Volume1,076,009
30 Day Avg. Volume1,273,168
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.10
Price to Sales (P/S)0.95
P/FCF Ratio16.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.28Price Target Upside40.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$838.77M
Integral Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across...
How the Company Makes Money
IDX primarily makes money by performing diagnostic imaging examinations and billing for those services. Revenue is generated across its network of imaging clinics from fees associated with imaging modalities and procedures (for example, radiology-...
Integral Diagnostics Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
55
Neutral
Cash Flow
70
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 788.62M | 627.22M | 469.70M | 440.10M | 358.74M |
| Gross Profit | 168.55M | 599.09M | 446.78M | 97.76M | 83.84M |
| EBITDA | 141.99M | 87.70M | 12.10M | 92.74M | 69.90M |
| Net Income | 21.93M | 4.67M | -60.70M | 25.04M | 14.60M |
Balance Sheet | |||||
| Total Assets | 1.46B | 1.43B | 744.28M | 839.01M | 783.01M |
| Cash, Cash Equivalents and Short-Term Investments | 51.29M | 52.10M | 42.44M | 33.85M | 123.19M |
| Total Debt | 597.10M | 585.01M | 355.59M | 365.08M | 340.99M |
| Total Liabilities | 778.69M | 732.53M | 442.57M | 465.96M | 435.77M |
| Stockholders Equity | 675.97M | 693.00M | 301.71M | 373.05M | 347.24M |
Cash Flow | |||||
| Free Cash Flow | 45.60M | 14.01M | 42.28M | 27.42M | 9.33M |
| Operating Cash Flow | 95.24M | 73.77M | 66.16M | 71.42M | 37.10M |
| Investing Cash Flow | -46.44M | -64.99M | -27.90M | -128.96M | -55.69M |
| Financing Cash Flow | -48.37M | 710.00K | -29.45M | -31.85M | 81.13M |
Integral Diagnostics Ltd. Technical Analysis
Positive
2.33
Price Trends
2.18
Positive
2.10
Positive
2.22
Positive
Market Momentum
0.04
Positive
52.32
Neutral
63.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Positive. The current price of 2.33 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.18, and above the 200-day MA of 2.22, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.32 is Neutral, neither overbought nor oversold. The STOCH value of 63.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDX.
Integral Diagnostics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | AU$9.70B | 15.64 | 7.20% | 5.61% | 15.53% | 15.11% | |
60 Neutral | AU$865.02M | 38.78 | 3.24% | 4.39% | 25.73% | 390.83% | |
54 Neutral | AU$537.17M | 23.30 | 15.80% | 4.51% | -0.90% | -25.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$323.15M | -0.66 | -114.08% | 35.60% | 2.16% | 21.04% | |
48 Neutral | AU$31.71M | -4.28 | -881.94% | ― | 743.51% | -1.52% | |
42 Neutral | AU$6.41M | -0.71 | 165.88% | ― | -100.00% | -3.67% |
* Healthcare Sector Average
AU:IDX
Integral Diagnostics Ltd.
2.28
-0.54
-19.01%
AU:HLS
Healius Limited
0.38
-0.40
-51.28%
AU:BDX
BCAL Diagnostics Limited
0.09
0.02
22.86%
AU:SHL
Sonic Healthcare Limited
19.24
-2.06
-9.66%
AU:ACL
Australian Clinical Labs Ltd
2.88
0.42
17.07%
AU:IBX
Imagion Biosystems Ltd.
0.01
-0.03
-74.36%
Integral Diagnostics Ltd. Corporate Events
Integral Diagnostics lifts earnings and dividend on strong FY26 performance
Aug 25, 2026
Integral Diagnostics reported strong full-year 2026 results, with revenue rising 25.6% to $788.7 million and operating EBITDA up 30.3% to $164.8 million, lifting the margin to 20.9%. Operating NPAT surged 50.1% to $47.4 million and operating dilut...
Integral Diagnostics Highlights Patient-Centric Vision in 2026 Annual Report
Aug 25, 2026
Integral Diagnostics Ltd. has released its 2026 Annual Report for the year ended 30 June 2026, highlighting its commitment to placing patients at the centre of its radiology and diagnostic operations. The report reinforces a corporate culture buil...
Integral Diagnostics Sets Key Dates for 2026 AGM and Director Nominations
Aug 20, 2026
Integral Diagnostics Limited, listed on the ASX as IDX, operates a network of medical imaging services across Australia and New Zealand, staffed by leading radiologists and diagnostic imaging specialists. The group’s medical leadership model...
Integral Diagnostics posts strong FY26 preliminary results and names new CFO
Aug 9, 2026
Integral Diagnostics reported preliminary unaudited FY26 results showing strong growth, with revenue rising about 25% to roughly $788–$790 million and operating EBITDA up around 30%, supported by a full-year contribution from Capitol Health....
Integral Diagnostics Appoints New Director With No Current Shareholdings
Aug 6, 2026
Integral Diagnostics Limited has appointed Jason Martinez as a director effective 6 August 2026, according to a filing with the ASX. The company reported that Martinez currently holds no relevant interests in the company’s securities, either...
Integral Diagnostics Details Final Director Interest as Ian Kadish Exits Board
Aug 6, 2026
Integral Diagnostics Ltd has announced that Ian Kadish has ceased to be a director of the company as of 6 August 2026, with a final notice lodged detailing his remaining interests in the group’s securities. The filing outlines his holdings i...
Integral Diagnostics Resets FY26 Results Call After Link Issue
Jul 23, 2026
Integral Diagnostics has re‑issued its notice to investors after a corrupted link in an earlier announcement detailing its FY26 results communications. The company clarified that it will release its FY26 results on the morning of 25 August 2...
Integral Diagnostics sets date for FY26 results release and investor call
Jul 23, 2026
Integral Diagnostics Limited has scheduled the release of its fiscal year 2026 results for the morning of Tuesday, 25 August 2026, followed by a group investor conference call at 11:00am AEST the same day. Investors in Australia and New Zealand wi...
Integral Diagnostics Director Increases Shareholding via Incentive Vesting
Jul 1, 2026
Integral Diagnostics has reported a change in the shareholding of director Ian Kadish following the vesting of short-term incentive performance rights. Kadish converted 37,678 STI performance rights into an equal number of fully paid ordinary shar...
Integral Diagnostics Issues 67,226 New Ordinary Shares After Option Conversions
Jul 1, 2026
Integral Diagnostics Ltd. has issued 67,226 new ordinary fully paid shares following the conversion or exercise of previously unquoted equity securities. The issuance, notified to the ASX under Appendix 3G and effective 1 July 2026, modestly incre...
Integral Diagnostics Director Increases Shareholding via On-Market Purchase
Jun 25, 2026
Integral Diagnostics Ltd. reported a change in the shareholding of director James Tobias Hall, reflecting an increase in his direct ownership of the company’s ordinary shares. The on-market purchase aligns his financial interests more closel...
Integral Diagnostics to Release 178,146 Escrowed Shares Without Capital Change
Jun 19, 2026
Integral Diagnostics will release 178,146 fully paid ordinary shares from voluntary escrow on 1 July 2026, in line with market disclosure requirements. The move does not alter the company’s issued capital, indicating no immediate dilution fo...
Integral Diagnostics orders audit after rebutting WA billing allegations
Jun 9, 2026
Integral Diagnostics has responded to media reports in Western Australia alleging inappropriate Medicare billing by its subsidiary Apex Radiology at Kalgoorlie Hospital, stating it is not aware of any improper practices. The company highlighted it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.